bioRxivImmunology
Landscape and Selection of Vaccine Epitopes in SARS-CoV-2
C. C. Smith, S. Entwistle, C. Willis, S. Vensko, W. Beck, J. Garness, M. Sambade, E. Routh, K. Olsen, J. Kodysh, T. O'Donnell, C. Haber, K. Heiss, V. Stadler, E. Garrison, O. C. Grant, R. Woods, M. Heise, B. G. Vincent, A. Rubinsteyn
Abstract
There is an urgent need for a vaccine with efficacy against SARS-CoV-2. We hypothesize that peptide vaccines containing epitope regions optimized for concurrent B cell, CD4+ T cell, and CD8+ T cell stimulation would drive both humoral and cellular immunity with high specificity, potentially avoiding undesired effects such as antibody-dependent enhancement (ADE). Additionally, such vaccines can be rapidly manufactured in a distributed manner. In this study, we combine computational prediction of T cell epitopes, recently published B cell epitope mapping studies, and epitope accessibility to select candidate peptide vaccines for SARS-CoV-2. We begin with an exploration of the space of possible T cell epitopes in SARS-CoV-2 with interrogation of predicted HLA-I and HLA-II ligands, overlap between predicted ligands, protein source, as well as concurrent human/murine coverage. Beyond MHC affinity, T cell vaccine candidates were further refined by predicted immunogenicity, viral source protein abundance, sequence conservation, coverage of high frequency HLA alleles and co-localization of CD4+ and CD8+ T cell epitopes. B cell epitope regions were chosen from linear epitope mapping studies of convalescent patient serum, followed by filtering to select regions with surface accessibility, high sequence conservation, spatial localization near functional domains of the spike glycoprotein, and avoidance of glycosylation sites. From 58 initial candidates, three B cell epitope regions were identified. By combining these B cell and T cell analyses, as well as a manufacturability heuristic, we propose a set of SARS-CoV-2 vaccine peptides for use in subsequent murine studies and clinical trials. O_FIG O_LINKSMALLFIG WIDTH=180 HEIGHT=200 SRC="FIGDIR/small/135004v1_ufig1.gif" ALT="Figure 1"> View larger version (40K): org.highwire.dtl.DTLVardef@1fc6599org.highwire.dtl.DTLVardef@1725a45org.highwire.dtl.DTLVardef@84a233org.highwire.dtl.DTLVardef@1b4c7aa_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: human
- assay: proteomics
- research focus: drug response / drug discovery
- approach: deep learning
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Immunoinformatic identification of B cell and T cell epitopes in the SARS-CoV-2 proteome
S. N. Crooke, I. G. Ovsyannikova, … G. A. Poland·bioRxiv·May 14, 2020
- Epitope-based peptide vaccines predicted against novel coronavirus disease caused by SARS-CoV-2
- Designing of Epitope-Based Vaccine from the Conserved Region of the Spike Glycoprotein of SARS-CoV-2
Vidhu Agarwal, Pritish Kumar Varadwaj, Akhilesh Tiwari·bioRxiv·Aug 27, 2020
- Design of an Epitope-Based Peptide Vaccine against the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): A Vaccine-informatics Approach
Aftab Alam, Arbaaz Khan, … Romana Ishrat·Briefings in BioinformaticsPeer-reviewed·Oct 28, 2020
- Immuno-informatics Design of a Multimeric Epitope Peptide Based Vaccine Targeting SARS-CoV-2 Spike Glycoprotein
O. S. Chukwudozie, C. M. Gray, … D. M. Eze·bioRxiv·Jul 30, 2020
- Multi-epitope vaccine design using an immunoinformatics approach for 2019 novel coronavirus (SARS-CoV-2)